换一批Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial.
第一作者：
Gunter,von Minckwitz
第一单位：
German Breast Group, Frankfurt, Germany. minckwitz@germanbreastgroup.de
作者：
医学主题词
成年人(Adult);老年人(Aged);抗生素类, 抗肿瘤(Antibiotics, Antineoplastic);抗代谢药, 抗肿瘤(Antimetabolites, Antineoplastic);抗肿瘤药, 烷基化(Antineoplastic Agents, Alkylating);抗肿瘤药, 植物(Antineoplastic Agents, Phytogenic);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);乳腺肿瘤(Breast Neoplasms);癌, 导管, 乳腺(Carcinoma, Ductal, Breast);癌, 小叶状(Carcinoma, Lobular);化学疗法, 辅助(Chemotherapy, Adjuvant);环磷酰胺(Cyclophosphamide);脱氧胞苷(Deoxycytidine);多柔比星(Doxorubicin);用药计划表(Drug Administration Schedule);女(雌)性(Female);氟尿嘧啶(Fluorouracil);德国(Germany);人类(Humans);乳房切除术, 区段(Mastectomy, Segmental);中年人(Middle Aged);肿瘤辅助疗法(Neoadjuvant Therapy);肿瘤分期(Neoplasm Staging);病人依从(Patient Compliance);前瞻性研究(Prospective Studies);紫杉烷类(Taxoids);治疗结果(Treatment Outcome);超声检查, 乳房(Ultrasonography, Mammary);长春碱(Vinblastine)
DOI
10.1093/jnci/djn085
PMID
18398097
发布时间
2024-12-19
- 浏览63
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
